CSL Response to Patent Complaint


FY2017 profit upgrade

12-April-2017 — CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims. More.

Half Year Result 2017


Half Year Results Announcement 2017

15-February-2017 — CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). More.


Other recent news:

10-February-2017 — An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes. More.
19-January-2017 — CSL Limited today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016. More.
09-January-2017 — CSL today announced that the European Commission has granted marketing authorisation for CSL Behring's AFSTYLA® for children and adults with haemophilia A. More.

© 2017 CSL Limited